Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling.

Edward ArmstrongMatthew K L ChiuShane FooLizzie AppletonPablo NenclaresAnton PatrikeevNitya MohanMartin MclaughlinGalabina BozhanovaJulia HoebartVictoria RoulstoneEmmanuel C Patin Malin PedersenJoan KyulaMasahiro OnoFiona Errington-Mais John Cameron Bell Kevin J Harrington Alan A Melcher Victoria Jennings

Published in: Journal for immunotherapy of cancer (2024)

Addition of αPD-1 to MG1 is required to overcome viral therapy resistance in immunologically 'colder' more advanced melanoma, highlighting the importance of tumor burden to different types of immunotherapy.

Keyphrases

sars cov
skin cancer
stem cells
risk factors
bone marrow
cell therapy